Sinovent Completes Pre-IPO Financing of at least $30 Million

Suzhou Sinovent completed a pre-IPO financing of at least $30 million in a round led by Oceanpine Healthcare Fund. Founded in 2016, Sinovent is a global biopharma that has 12 biologic products in development, five in clinical trials and another three molecules preparing to file INDs in China . Its lead program is a Wnt pathway porcupine inhibitor aimed at cancers of the digestive system, including colon cancer, esophageal cancer and gastric cancer. In August of last year, Sinovent completed a $145 million C round.  More details.... Share this with colleagues: // //